Armata Pharmaceuticals, Inc.
AP-SA02
complicated bacteremia caused by Staphylococcus aureus
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on AP-SA02 for complicated bacteremia caused by Staphylococcus aureus is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“Announced that the FDA granted AP-SA02 for intravenous use as a QIDP for adjunct treatment of complicated SAB caused by MSSA or MRSA.”